Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy — Efstathios Kastritis (2015) | RDL Network
Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy
Letter 2015 en
Authors
EK
Efstathios Kastritis
MK
Maria‐Christina Kyrtsonis
PM
Pierre Morel
Abstract
1 min read
WM is a disease of the elderly with a protracted course in many patients and a median survival of 7 to 10 years,[1][1] however, in many patients, other factors rather than WM or its treatment may be the cause of death.[2][2] Non-WM-related mortality mainly affects outcomes of elderly patients and is
Discussion(0)
No comments yet. Be the first to comment.